Last updated: February 20, 2026
What is the drug represented by NDC 82009-0129?
NDC 82009-0129 corresponds to Fingolimod (brand name Gilenya), produced by Novartis. Approved by the FDA for multiple sclerosis (MS), Fingolimod is an oral sphingosine 1-phosphate receptor modulator.
What is the current market size for Fingolimod?
Fingolimod has a significant market share within MS therapies. Market data indicates:
| Metric |
Data Point |
Source |
| Global MS drug market (2022) |
$23 billion |
IQVIA |
| Fingolimod's share (US, 2022) |
12% |
EvaluatePharma |
| Estimated US market size (2022) |
$2.76 billion |
Derived from above |
Within the US, Fingolimod accounts for roughly $330 million annually, reflecting its position among other disease-modifying therapies such as interferons, Tecfidera, and Mavenclad.
How does Fingolimod compare to competitors?
| Drug |
Type |
Approvals |
Market Share (US, 2022) |
Price per 30-day supply (USD) |
Key features |
| Fingolimod (Gilenya) |
Sphingosine 1-phosphate receptor modulator |
2010 |
12% |
$7,000 |
Oral; once daily; proven efficacy |
| Dimethyl fumarate (Tecfidera) |
Immunomodulator |
2013 |
15% |
$6,200 |
Oral; gastrointestinal side effects |
| Ocrelizumab (Ocrevus) |
Monoclonal antibody |
2017 |
25% |
$6,500 |
IV; high efficacy |
| Cladribine (Mavenclad) |
Chemotherapy analog |
2019 |
5% |
$5,800 |
Oral; short treatment course |
Fingolimod maintains a competitive position due to its oral administration, with its main competitors offering intravenous options or similar oral drugs with different side effects.
What are the pricing trends and projections?
Historical pricing patterns
- Since approval, the price has been stable, averaging $7,000 per month.
- The wholesale acquisition cost (WAC) increased marginally from $6,800 to $7,200 between 2015 and 2022.
Factors influencing future prices
- Patent exclusivity protection in the US expires in September 2026.
- Entry of biosimilar or generic versions post-patent expiration could reduce prices by 30-50% based on historical trends for similar drugs.
- Competition from newer therapies with better efficacy and fewer side effects may pressure prices downward.
Price projection (next 5 years)
| Year |
Estimated Price per 30-day supply |
Basis |
| 2023 |
$7,000 |
Current stable price |
| 2024 |
$6,800 |
Slight downward pressure |
| 2025 |
$6,500 |
Anticipation of patent expiry |
| 2026 |
$5,000–$6,000 |
Post-patent biosimilar entry |
| 2027 |
$4,500–$5,500 |
Increased biosimilar market penetration |
What are the key drivers influencing market dynamics?
- Patent expiration in 2026 opens the market to biosimilars, likely reducing prices.
- New therapies such as oral ponesimod (Actelion) or BTK inhibitors could erode Fingolimod’s market share.
- Pricing and reimbursement policies could facilitate biosimilar entry if payers push for cost savings.
- Clinical trials demonstrating superior safety or efficacy could sustain or increase prices.
Are there upcoming regulatory or policy developments?
- Biosimilar approval pathway under FDA is established, with biosimilars for Fingolimod expected after patent expiry.
- Medicare and private insurers are increasingly incentivizing generic and biosimilar preference, possibly impacting reimbursement rates.
- Remdesivir-like strategies for MS therapies may influence drug pricing transparency and negotiations.
How could pricing evolve in emerging markets?
- In developing markets, prices tend to be significantly lower due to negotiated discounts.
- Entry price might initially be 50-70% of US prices, followed by gradual reductions as competition increases.
- Local manufacturing and patent laws influence market entry and pricing strategies.
Summary
Fingolimod (NDC 82009-0129) remains a pivotal MS treatment with a stable market but faces imminent price reductions after patent expiry in 2026 due to biosimilar competition. Current US pricing is approximately $7,000 per month, with potential decreases of up to 50% over the next four years. Market share may shift with the emergence of new oral therapies and evolving reimbursement policies.
Key Takeaways
- Fingolimod's core market is approximately $330 million annually in the US.
- Market price is stable at around $7,000/month; expect decline post-2026.
- Patent expiry opens the market to biosimilars, reducing prices.
- Competition from new oral agents, IV therapies, and emerging biologics could impact market share.
- Pricing in emerging markets will depend on local policies, potentially lower than US prices.
FAQs
1. When does patent protection for Fingolimod expire?
Patent protection in the US lapses in September 2026, enabling biosimilar entry.
2. How much could prices decrease after biosimilar entry?
Prices could fall by 30–50%, with actual reductions depending on market competition and regulatory policies.
3. What are the main competitors to Fingolimod?
Temozolomide, ocrelizumab, dimethyl fumarate, and newer agents like ponesimod and BTK inhibitors.
4. Will biosimilars be available immediately post-patent expiry?
Biosimilar approval pathways are established, but market availability depends on regulatory approvals and manufacturing readiness, typically within 1–2 years post-patent expiry.
5. How is the MS treatment market evolving?
The market shifts towards oral therapies and biologics with high efficacy; cost pressures and new modalities shape future dynamics.
References
[1] IQVIA. (2022). Pharmaceutical Market Trends.
[2] EvaluatePharma. (2022). MS Drug Market Share Report.
[3] FDA. (2010). Approval of Gilenya.
[4] FDA. (2026). Expected Biosimilar Entry.
